Heat Biologics Files IND for Bladder Cancer Product Candidate

Heat Biologics, Inc.

, a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for its second product candidate, HS-410, which will be evaluated in bladder cancer. The Company also named Melissa Price, Ph.D., as Vice President, Clinical and Regulatory Affairs. Dr. Price will be responsible for the implementation of Heat's HS-410 bladder cancer program, as well as all of the Company's clinical studies. Dr. Price will also direct the company's regulatory strategy.